Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes

2 Information about ertugliflozin

**Information about ertugliflozin**
Marketing authorisation indication	Ertugliflozin (Steglatro, Merck Sharp & Dohme) is indicated 'in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: as monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications in addition to other medicinal products for the treatment of diabetes.'
Dosage in the marketing authorisation	The recommended dosage for monotherapy is 5 mg once daily, increasing to 15 mg once daily if additional glycaemic control is needed. In combination therapy, dosage should be individualised using the recommended daily dose of 5 mg or 15 mg.
Price	The list price for 28 tablets of ertugliflozin 5 mg or 15 mg is £29.40 per pack (company submission). Costs may vary in different settings because of negotiated procurement discounts.